{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:28:52Z","timestamp":1746786532829},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00347-018-0825-7","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T16:17:17Z","timestamp":1543940237000},"page":"332-339","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neue therapeutische M\u00f6glichkeiten bei iridozili\u00e4ren Tumoren"],"prefix":"10.1007","volume":"116","author":[{"given":"J. M.","family":"Mor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. R.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Kakkassery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cursiefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"825_CR1","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN et al (2016) Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122:3344\u20133353","journal-title":"Cancer"},{"key":"825_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00347-017-0571-2","volume":"115","author":"G Avgitidou","year":"2018","unstructured":"Avgitidou G, Heindl LM, Cursiefen C (2018) Block excision with tectonic corneoscleral graft for traumatic pediatric epithelial implantation cysts. Ophthalmologe 115:67\u201370","journal-title":"Ophthalmologe"},{"key":"825_CR3","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1055\/s-0043-114421","volume":"234","author":"G Blatsios","year":"2017","unstructured":"Blatsios G, Haas G, Zehetner C et\u00a0al (2017) Surgical methods in the treatment of uveal melanoma. Klin Monbl Augenheilkd 234:874\u2013885","journal-title":"Klin Monbl Augenheilkd"},{"key":"825_CR4","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.ophtha.2016.06.027","volume":"123","author":"KF Bol","year":"2016","unstructured":"Bol KF, van den Bosch T, Schreibelt G et al (2016) Adjuvant dendritic cell vaccination in high-risk uveal melanoma. Ophthalmology 123:2265\u20132267","journal-title":"Ophthalmology"},{"key":"825_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ophtha.2017.02.015","volume":"124","author":"SS Chaugule","year":"2017","unstructured":"Chaugule SS, Finger PT (2017) Regression patterns of Iris melanoma after palladium-103 (103Pd) plaque brachytherapy. Ophthalmology 124:1023\u20131030","journal-title":"Ophthalmology"},{"key":"825_CR6","first-page":"1684","volume":"124","author":"Collaborative Ocular Melanoma Study Group","year":"1693","unstructured":"Collaborative Ocular Melanoma Study Group (1693) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma (2006) V. Twelve-year mortality rates and prognostic factors. COMS Report No. 28. Arch Ophthalmol 124:1684","journal-title":"Arch Ophthalmol"},{"key":"825_CR7","doi-asserted-by":"publisher","first-page":"848e54","DOI":"10.1136\/bjo.85.7.848","volume":"85","author":"RM Conway","year":"2001","unstructured":"Conway RM, Chua WCT, Qureshi C et\u00a0al (2001) Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 85:848e54","journal-title":"Br J Ophthalmol"},{"key":"825_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/archopht.117.1.113","volume":"117","author":"C Cursiefen","year":"1999","unstructured":"Cursiefen C, Schl\u00f6tzer-Schrehardt U, Holbach LM et al (1999) Adenoma of the nonpigmented ciliary epithelium mimicking a\u00a0malignant melanoma of the iris. Arch Ophthalmol 117:113\u2013116","journal-title":"Arch Ophthalmol"},{"key":"825_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijrobp.2005.01.050","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Kacperek A, Chopra M et\u00a0al (2005) Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys 63:109\u2013115","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"825_CR10","first-page":"1553e60","volume":"109","author":"H Demirci","year":"2002","unstructured":"Demirci H, Shields CL, Shields JA et\u00a0al (2002) Diffuse iris melanoma: a\u00a0report of 25 cases. Ophthalmology 109:1553e60","journal-title":"Ophthalmology"},{"key":"825_CR11","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0360-3016(02)03751-3","volume":"54","author":"PT Finger","year":"2002","unstructured":"Finger PT, Berson A, Ng T et al (2002) Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys 54:1438\u20131445","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"825_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00417-013-2510-5","volume":"252","author":"LM Heindl","year":"2014","unstructured":"Heindl LM, Bucher F, Naumann GO et\u00a0al (2014) Lack of ciliary body lymphatics in iridociliary melanocytoma. Graefes Arch Clin Exp Ophthalmol 252:169\u2013171","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"825_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ophtha.2009.06.057","volume":"117","author":"LM Heindl","year":"2010","unstructured":"Heindl LM, Hofmann TN, Adler W et al (2010) Intraocular tumor-associated lymphangiogenesis a\u00a0novel prognostic factor for ciliary body melanomas with extraocular extension? Ophthalmology 117:334\u2013342","journal-title":"Ophthalmology"},{"key":"825_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ophtha.2016.09.011","volume":"124","author":"LM Heindl","year":"2017","unstructured":"Heindl LM, Koch KR, Hermann MM et\u00a0al (2017) Block excision of iridociliary tumors enables molecular profiling and immune vaccination. Ophthalmology 124:268\u2013270","journal-title":"Ophthalmology"},{"key":"825_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00347-006-1451-3","volume":"104","author":"LM Heindl","year":"2007","unstructured":"Heindl LM, Lotter M, Strnad V, Sauer R, Naumann GO, Knorr HL (2007) High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study. Ophthalmologe 104:149\u2013157","journal-title":"Ophthalmologe"},{"key":"825_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/PPO.0000000000000242","volume":"23","author":"WT Iams","year":"2017","unstructured":"Iams WT, Sosman JA, Chandra S (2017) Novel targeted therapies for metastatic melanoma. Cancer\u00a0J 23:54\u201358","journal-title":"Cancer J"},{"key":"825_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jcrs.2013.08.051","volume":"40","author":"KR Koch","year":"2014","unstructured":"Koch KR, Heindl LM, Cursiefen C et\u00a0al (2014) Artificial iris devices: benefits, limitations, and management of complications. J\u00a0Cataract Refract Surg 40:376\u2013382","journal-title":"J Cataract Refract Surg"},{"key":"825_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.eye.6701361","volume":"18","author":"L Lumbroso-Le Rouic","year":"2004","unstructured":"Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C et al (2004) 125I plaque brachytherapy for anterior uveal melanomas. Eye (Lond) 18:911\u2013916","journal-title":"Eye (Lond)"},{"key":"825_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/ceo.13041","volume":"46","author":"JJ Meyer","year":"2018","unstructured":"Meyer JJ, Krishnan T, McGhee CN (2018) Minimal iris touch excision: a\u00a0novel surgical technique for local excision of iris melanoma. Clin Exp Ophthalmol 46:298\u2013299","journal-title":"Clin Exp Ophthalmol"},{"key":"825_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1055\/s-0043-120093","volume":"234","author":"JM Mor","year":"2017","unstructured":"Mor JM, Koch KR, Heindl LM (2017) Diagnosis and therapy of Iris lesions. Klin Monbl Augenheilkd 234:1541\u20131554","journal-title":"Klin Monbl Augenheilkd"},{"key":"825_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-68366-7","volume-title":"Applied pathology for ophthalmic microsurgeons","author":"GO Naumann","year":"2008","unstructured":"Naumann GO (2008) Iris. In: Naumann GOH, Holbach LM, Kruse FE (Hrsg) Applied pathology for ophthalmic microsurgeons, 1.\u00a0Aufl. Springer, Berlin, Heidelberg","edition":"1"},{"key":"825_CR22","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/S0161-6420(96)30392-8","volume":"103","author":"GO Naumann","year":"1996","unstructured":"Naumann GO, Rummelt V (1996) Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology 103:2017\u20132027 (discussion 2027\u20138)","journal-title":"Ophthalmology"},{"key":"825_CR23","first-page":"9033","volume":"32","author":"JM Piulats Rodriguez","year":"2014","unstructured":"Piulats Rodriguez JM, Ochoa de Olza M, Codes M et al (2014) Phase II study evaluating ipilimumab as a\u00a0single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial. ASCO Meet Abstr 32:9033","journal-title":"ASCO Meet Abstr"},{"key":"825_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.survophthal.2016.12.012","volume":"62","author":"M Popovic","year":"2017","unstructured":"Popovic M, Ahmed IIK, DiGiovanni J et\u00a0al (2017) Radiotherapeutic and surgical management of iris melanoma: a review. Surv Ophthalmol 62:302\u2013311","journal-title":"Surv Ophthalmol"},{"key":"825_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00066-017-1166-1","volume":"193","author":"AI Riechardt","year":"2017","unstructured":"Riechardt AI, Karle B, Cordini D, Heufelder J, Budach V, Joussen AM, Gollrad J (2017) Proton therapy of iris melanoma with 50 CGE : influence of target volume on clinical outcome. Strahlenther Onkol 193:943\u2013950","journal-title":"Strahlenther Onkol"},{"key":"825_CR26","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00417-018-3929-5","volume":"256","author":"AI Riechardt","year":"2018","unstructured":"Riechardt AI, Klein JP, al Cordini D (2018) Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects. Graefes Arch Clin Exp Ophthalmol 256:1325\u20131332","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"825_CR27","volume-title":"Pathologie des Auges II","author":"V Rummelt","year":"1997","unstructured":"Rummelt V, Naumann GOH (1997) Uvea. In: Naumann GOH (Hrsg) Pathologie des Auges II, 2.\u00a0Aufl. Springer, Berlin, Heidelberg","edition":"2"},{"key":"825_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0371-7","author":"B Schneider","year":"2017","unstructured":"Schneider B, Riedel K, Zhivov A et\u00a0al (2017) Frequent and yet unreported GNAQ and GNA11 mutations are found in uveal melanomas. Pathol Oncol Res. \n                    https:\/\/doi.org\/10.1007\/s12253-017-0371-7","journal-title":"Pathol Oncol Res"},{"key":"825_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00347-015-0162-z","volume":"112","author":"B Schuler-Thurner","year":"2015","unstructured":"Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N et al (2015) Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma. Ophthalmologe 112:1017\u20131021","journal-title":"Ophthalmologe"},{"key":"825_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ophtha.2011.09.039","volume":"119","author":"SU Shah","year":"2012","unstructured":"Shah SU, Shields CL, Bianciotto C et\u00a0al (2012) Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases. Ophthalmology 119:838\u2013842.e2","journal-title":"Ophthalmology"},{"key":"825_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jamaophthalmol.2014.160","volume":"132","author":"CL Shields","year":"2014","unstructured":"Shields CL, Arepalli S, Lally EB et al (2014) Iris stromal cyst management with absolute alcohol-induced sclerosis in 16 patients. Jama Ophthalmol 132:703\u2013708","journal-title":"Jama Ophthalmol"},{"key":"825_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields CL, Furuta M, Thangappan A et al (2009) Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 127:989\u2013998","journal-title":"Arch Ophthalmol"},{"key":"825_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2011.07.059","volume":"119","author":"CL Shields","year":"2012","unstructured":"Shields CL, Kancherla S, Patel J et\u00a0al (2012) Clinical survey of 3680 iris tumors based on patient age at presentation. Ophthalmology 119:407\u2013414","journal-title":"Ophthalmology"},{"key":"825_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0002-9394(02)02241-9","volume":"135","author":"CL Shields","year":"2003","unstructured":"Shields CL, Naseripour M, Shields JA et al (2003) Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol 135:648\u2013656","journal-title":"Am J Ophthalmol"},{"key":"825_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0161-6420(00)00449-8","volume":"108","author":"CL Shields","year":"2001","unstructured":"Shields CL, Shields JA, Materin M et\u00a0al (2001) Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 108:172\u2013178","journal-title":"Ophthalmology"},{"key":"825_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.22608\/APO.201705","volume":"6","author":"JA Shields","year":"2017","unstructured":"Shields JA, Shields CL (2017) Tumors and related lesions of the pigmented epithelium. Asia Pac J Ophthalmol (Phila) 6:215\u2013223","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"825_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ophtha.2017.10.009","volume":"125","author":"J Thariat","year":"2018","unstructured":"Thariat J, Rahmi A, Salleron J et\u00a0al (2018) Proton beam therapy for Iris melanomas in 107 patients. Ophthalmology 125:606\u2013614","journal-title":"Ophthalmology"},{"key":"825_CR38","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/bjophthalmol-2014-305174","volume":"99","author":"GD Willerding","year":"2015","unstructured":"Willerding GD, Cordini D, Hackl C (2015) Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol 99:812\u2013816","journal-title":"Br J Ophthalmol"},{"key":"825_CR39","doi-asserted-by":"crossref","first-page":"175883401875717","DOI":"10.1177\/1758834018757175","volume":"10","author":"J Yang","year":"2018","unstructured":"Yang J, Manson DK, Marr BP et\u00a0al (2018) Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol 10:1758834018757175","journal-title":"Ther Adv Med Oncol"},{"key":"825_CR40","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1088\/0031-9155\/52\/19\/016","volume":"52","author":"A Zytkovicz","year":"2007","unstructured":"Zytkovicz A, Daftari I, Phillips TL (2007) Peripheral dose in ocular treatments with cyberknife and gamma knife radiosurgery compared to proton radiotherapy. Phys Med Biol 52:5957\u20135971","journal-title":"Phys Med Biol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-018-0825-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:08:36Z","timestamp":1575418116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-018-0825-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1007\/s00347-018-0825-7","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"4 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.M.\u00a0Mor, K.R.\u00a0Koch, V.\u00a0Kakkassery, C.\u00a0Cursiefen und L.M.\u00a0Heindl geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Es handelt sich um eine reine Literatur\u00fcbersicht auf Basis publizierter Daten, sodass hier keine ethischen Konflikte vorliegen. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht m\u00fcndigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}